Key result
Plasma adiponectin levels were significantly lower in patients with type 2 diabetes compared to healthy controls, and further reduced in obese diabetic patients with cardiovascular disease.
Why the study?
Are adiponectin levels altered in patients with type 2 diabetes mellitus compared to healthy controls?
Case-Control (n=73)
Are adiponectin levels altered in patients with type 2 diabetes mellitus compared to healthy controls?
Adiponectin levels are significantly reduced in patients with type 2 diabetes, particularly those with obesity and cardiovascular disease, highlighting its potential role in the pathogenesis of insulin resistance and atherosclerosis.
No takes yet. Share an insight, caveat, or question.
Reduced adiponectin in T2DM with obesity and CVD supports further study of its role; hypothesis-generating and should not yet change practice.
El-Nuweihy et al. (2010) conducted a case-control in Non-insulin dependent diabetes mellitus (n=73). Type 2 diabetes mellitus vs. Healthy controls was evaluated on Plasma adiponectin levels. Plasma adiponectin levels were significantly lower in patients with type 2 diabetes compared to healthy controls, and further reduced in obese diabetic patients with cardiovascular disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: